Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses.
Antibody
B cells
CD8 T cells
Gp96
Heat shock protein
OX40L
SARS-CoV-2 protein S
TFH cells
Vaccine
Journal
Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
15
12
2021
revised:
15
04
2022
accepted:
29
07
2022
pubmed:
9
8
2022
medline:
9
8
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Encouraging protection results from current mRNA-based SARS-CoV-2 vaccine platforms are primarily due to the induction of SARS- CoV-2- specific B cell antibody and CD4 + T cell. Even though, current mRNA vaccine platforms are adept in inducing SARS-CoV2-specific CD8 + T cell, much less is known about CD8 T cells contribution to the overall vaccine protection. Our allogeneic cellular vaccine, based on a secreted form of the heat-shock protein gp96-Ig, achieves high frequencies of polyclonal CD8 + T cell responses to tumor and infectious antigens through antigen cross-priming
Identifiants
pubmed: 35936992
doi: 10.1016/j.jvacx.2022.100202
pii: S2590-1362(22)00062-6
pmc: PMC9347141
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100202Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM112601
Pays : United States
Informations de copyright
© 2022 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
NS is inventor on the patent application No 62/983,783 entitled “Immune-mediated coronavirus treatments”; NS is a member of Heat Biologics COVID-19 Advisory Board. MMS is the Vice President of Research; ED is the Executive Director of Research.; PJ is the Director of Business Development, all are employed by Heat Biologics, Inc. RJ is the CEO of Pelican Therapeutics, a subsidiary of Heat Biologics, Inc. MMS, ED, PJ, RJ, and KP hold stock options in Heat Biologics, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res. 1999 Sep 15;59(18):4642-50
pubmed: 10493519
Immunol Rev. 2009 May;229(1):173-91
pubmed: 19426222
J Immunol. 2005 Sep 15;175(6):3534-41
pubmed: 16148096
Nature. 2021 Sep;597(7875):268-273
pubmed: 34320609
Immunity. 2010 Aug 27;33(2):241-53
pubmed: 20691615
Immunity. 1995 May;2(5):507-21
pubmed: 7749983
Am J Clin Oncol. 1997 Aug;20(4):398-403
pubmed: 9256898
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13138-43
pubmed: 16924108
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6128-33
pubmed: 15073331
J Immunol. 2006 Oct 1;177(7):4464-72
pubmed: 16982882
J Immunol. 2005 Aug 1;175(3):1665-76
pubmed: 16034107
Immunol Rev. 2011 Nov;244(1):149-68
pubmed: 22017437
Microbes Infect. 2008 Jul;10(9):1024-9
pubmed: 18662798
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
J Immunol. 2007 Oct 15;179(8):5099-108
pubmed: 17911595
J Immunol. 2007 Dec 1;179(11):7254-61
pubmed: 18025167
J Immunol. 2007 Aug 15;179(4):2195-202
pubmed: 17675479
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Front Immunol. 2021 Jan 26;11:602254
pubmed: 33584668
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Immunity. 2009 Mar 20;30(3):324-35
pubmed: 19303387
J Immunol. 2013 Mar 15;190(6):2495-9
pubmed: 23401588
Eur J Immunol. 2009 Nov;39(11):3110-20
pubmed: 19839010
Annu Rev Immunol. 2016 May 20;34:335-68
pubmed: 26907215
J Immunol. 2007 Aug 15;179(4):2310-7
pubmed: 17675492
J Immunol. 1989 Feb 15;142(4):1366-71
pubmed: 2464645
J Exp Med. 2000 Dec 4;192(11):1553-62
pubmed: 11104798
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Proc Natl Acad Sci U S A. 1986 May;83(10):3407-11
pubmed: 3458189
Immunol Cell Biol. 2011 Mar;89(3):340-5
pubmed: 21301482
Int Immunol. 2004 Apr;16(4):615-24
pubmed: 15039392
J Immunother Cancer. 2018 Dec 18;6(1):149
pubmed: 30563566
J Exp Med. 1994 Aug 1;180(2):757-62
pubmed: 7913952
J Immunol. 1998 Dec 15;161(12):6510-7
pubmed: 9862675
Technol Cancer Res Treat. 2013 Aug;12(4):285-93
pubmed: 23448575
J Immunol. 1997 Oct 15;159(8):3838-48
pubmed: 9378971
Science. 2020 Sep 25;369(6511):1586-1592
pubmed: 32694201
Immunol Res. 2013 Dec;57(1-3):311-25
pubmed: 24254084
Immunity. 2003 Mar;18(3):381-90
pubmed: 12648455
Blood. 2004 Oct 1;104(7):1952-60
pubmed: 15213097
Mucosal Immunol. 2010 Mar;3(2):182-92
pubmed: 19924120
Nat Commun. 2017 May 31;8:15648
pubmed: 28561043
Curr Opin Immunol. 2019 Dec;61:1-9
pubmed: 31374450
JCI Insight. 2018 Dec 20;3(24):
pubmed: 30568041
Eur J Immunol. 2021 Jun;51(6):1325-1333
pubmed: 33788271
Vaccine. 2011 Mar 21;29(14):2619-25
pubmed: 21277409
Front Immunol. 2021 Jun 21;12:670637
pubmed: 34234777
J Immunol. 1999 Nov 15;163(10):5178-82
pubmed: 10553037
J Immunol. 2004 Apr 15;172(8):4821-5
pubmed: 15067059
Expert Opin Biol Ther. 2007 Nov;7(11):1679-88
pubmed: 17961091
Nat Rev Immunol. 2002 Mar;2(3):185-94
pubmed: 11913069
J Immunol. 1999 Feb 1;162(3):1818-26
pubmed: 9973447
Blood. 2005 Sep 15;106(6):1924-31
pubmed: 15899919